ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01063829
Recruitment Status : Completed
First Posted : February 5, 2010
Results First Posted : February 13, 2018
Last Update Posted : February 13, 2018
Sponsor:
Collaborator:
Quintiles, Inc.
Information provided by (Responsible Party):
AiCuris Anti-infective Cures GmbH

Brief Summary:
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).

Condition or disease Intervention/treatment Phase
HCMV Reactivation or HCMV End-Organ Disease Drug: 60 mg AIC246 Drug: 120 mg AIC246 Drug: 240 mg AIC246 Other: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 133 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug
Study Start Date : March 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: Dose regimen 1
60 mg AIC246, one tablet per day
Drug: 60 mg AIC246
Oral administration

Experimental: Dose regimen 2
120 mg AIC246, one tablet per day
Drug: 120 mg AIC246
Oral administration

Experimental: Dose regimen 3
240 mg AIC246, one tablet per day
Drug: 240 mg AIC246
Oral administration

Placebo
Placebo arm
Other: Placebo
Oral administration




Primary Outcome Measures :
  1. Number of Participants With "HCMV Prophylaxis Failure" [ Time Frame: 84 days ]
  2. Time to Onset of "HCMV Prophylaxis Failure" [ Time Frame: 84 days ]

Secondary Outcome Measures :
  1. Number of Patients With Systemic Detectable HCMV Replication. [ Time Frame: 84 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Seropositive for HCMV IgG antibodies before transplantation
  • First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder
  • Evidence of post transplantation engraftment
  • Able to swallow tablets.

Exclusion Criteria:

  • Previous anti-HCMV therapy after this allogeneic HBPC transplantation
  • Mismatched or cord blood transplant recipients
  • Current or history of end-organ HCMV disease
  • Graft versus host disease (GVHD)
  • Impaired liver function
  • Reduced renal function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01063829


Locations
United States, California
UCLA Medical Center
Los Angeles, California, United States
Stanford University Hospital
Stanford, California, United States
United States, Colorado
Denver St. Lukes Presbyterian
Denver, Colorado, United States
United States, Florida
University of Florida
Gainesville, Florida, United States
United States, Illinois
University of Chicago Medical Center
Chicago, Illinois, United States
Loyola University Chicago
Maywood, Illinois, United States
United States, Indiana
Indiana BMT
Beech Grove, Indiana, United States
United States, Iowa
University Of Iowa
Iowa City, Iowa, United States
United States, Massachusetts
Dana Farber Cancer Institute,
Boston, Massachusetts, United States
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States
United States, Pennsylvania
Jeanes Hospital of TUHS
Philadelphia, Pennsylvania, United States
UPMC Cancer Center
Pittsburgh, Pennsylvania, United States
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States
Germany
Universitaetsklinikum Dresden
Dresden, Germany
Universitaetsklinikum Erlangen-PS
Erlangen,, Germany
Universitätsklinikum Freiburg
Freiburg, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaeetsklinikum Heidelberg, ,
Heidelberg, Germany
Universitaetsklinikum Mainz
Mainz, Germany
Universitaetsklinikum Muenster
Muenster, Germany
Klinikum Nuernberg Nord
Nuernberg, Germany
Robert-Bosch-Krankenhaus
Stuttgart, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Sponsors and Collaborators
AiCuris Anti-infective Cures GmbH
Quintiles, Inc.

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AiCuris Anti-infective Cures GmbH
ClinicalTrials.gov Identifier: NCT01063829     History of Changes
Other Study ID Numbers: AIC246-01-II-02
First Posted: February 5, 2010    Key Record Dates
Results First Posted: February 13, 2018
Last Update Posted: February 13, 2018
Last Verified: December 2010

Keywords provided by AiCuris Anti-infective Cures GmbH:
HCMV

Additional relevant MeSH terms:
Antiviral Agents
Anti-Infective Agents